Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Department of Forensic Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
J Clin Periodontol. 2021 May;48(5):627-637. doi: 10.1111/jcpe.13447. Epub 2021 Mar 12.
To investigate secular trends in severe periodontitis incidence, prevalence and disability-adjusted life year (DALY) rates in China, India, Japan, South Korea and Thailand from 1990 to 2017.
Data were obtained from the "Global Burden of Disease Study" 2017. The annual percentage change and average annual percentage change were calculated using Joinpoint regression analysis. The independent age, period and cohort effects were estimated by age-period-cohort analysis.
From 1990 to 2017, the overall age-standardized incidence, prevalence and DALY rates increased in China, Japan and India, while decreasing in South Korea and Thailand. The highest incidence, prevalence and DALY rates were in India. By APC analysis, the age effect presented increase in 20-59 years in China, Japan and South Korea, 20-54 years in India and 20-64 years in Thailand; the period effect showed progressive increases in five countries, with the most significant increase shown in China; the cohort effect showed monotonic decreases with birth cohort in five countries.
Severe periodontitis poses a serious burden in Asian countries, especially China and India. We suggest raising people's awareness of periodontal health and providing professional interventions in these countries, especially for high-risk groups, such as younger people aged ≤65 years.
调查 1990 年至 2017 年期间中国、印度、日本、韩国和泰国严重牙周炎发病率、患病率和伤残调整生命年(DALY)率的变化趋势。
数据来源于 2017 年“全球疾病负担研究”。采用 Joinpoint 回归分析计算年度变化百分比和平均年度变化百分比。采用年龄-时期-队列分析估计独立的年龄、时期和队列效应。
1990 年至 2017 年期间,中国、日本和印度的牙周炎年龄标准化发病率、患病率和 DALY 率总体呈上升趋势,而韩国和泰国则呈下降趋势。印度的发病率、患病率和 DALY 率最高。通过 APC 分析,中国、日本和韩国的年龄效应在 20-59 岁时呈上升趋势,印度在 20-54 岁时呈上升趋势,泰国在 20-64 岁时呈上升趋势;时期效应显示五个国家的情况均呈逐步上升趋势,其中中国的上升幅度最大;队列效应显示五个国家的出生队列均呈单调下降趋势。
严重牙周炎在亚洲国家造成了严重的负担,特别是中国和印度。我们建议提高人们对牙周健康的认识,并在这些国家提供专业干预措施,特别是针对年轻人(≤65 岁)等高危人群。